Cancer Biology & Medicine

Papers
(The TQCC of Cancer Biology & Medicine is 7. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-12-01 to 2025-12-01.)
ArticleCitations
Mitochondrial transplantation sensitizes chemotherapy to inhibit tumor development by enhancing anti-tumor immunity191
Eliminating cervical cancer: a global health imperative for women97
Phase I study of chlorogenic acid injection for recurrent high-grade glioma with long-term follow-up66
Early-onset gastric cancer global burden profile, trends, and contributors57
Unraveling vascular mechanisms in melanoma: roles of angiogenesis and vasculogenic mimicry in tumor progression and therapeutic resistance54
The Warburg effect drives dedifferentiation through epigenetic reprogramming45
Optimizing the cancer research landscape for the benefit of patients and society: A strategic perspective of the German Cancer Research Center (DKFZ) and its partnerships with university medical cente44
Stability and variability of molecular subtypes: comparative analysis of primary and metastatic triple-negative breast cancer43
Role of the tumor microenvironment in shaping IDH-wildtype glioma plasticity, and potential therapeutic strategies43
ENO1 expression and Erk phosphorylation in PDAC and their effects on tumor cell apoptosis in a hypoxic microenvironment41
Associations between polymorphisms in leptin and leptin receptor genes and colorectal cancer survival41
PD-1 inhibitors provide new opportunities in conversion therapy for stage IV gastric cancer37
Biological mechanism and immune response of MHC-II expression in tumor cells35
Cancer-derived exosomal circTMEM56 enhances the efficacy of HCC radiotherapy through the miR-136-5p/STING axis34
Cancer stem cells: a target for overcoming therapeutic resistance and relapse33
Chinese Society of Clinical Oncology Non-small Cell Lung Cancer (CSCO NSCLC) guidelines in 2024: key update on the management of early and locally advanced NSCLC31
ACSL3 regulates breast cancer progression via lipid metabolism reprogramming and the YES1/YAP axis27
Immune checkpoint inhibitors: breakthroughs in cancer treatment27
A machine learning model to predict efficacy of neoadjuvant therapy in breast cancer based on dynamic changes in systemic immunity26
Cancer cell-derived migrasomes harboring ATF6 promote breast cancer brain metastasis via endoplasmic reticulum stress-mediated disruption of the blood-brain barrier25
Nodal peripheral T-cell lymphomas in the new classification systems24
Effects of Helicobacter pylori eradication on the profiles of blood metabolites and their associations with the progression of gastric lesions: a24
Advances in lung cancer screening and early detection24
Facing challenges with hope: universal immune cells for hematologic malignancies22
Current treatment paradigm and survival outcomes among patients with newly diagnosed multiple myeloma in China: a retrospective multicenter study22
Human papillomavirus vaccination willingness under resource inequities: momentary intervention effects of an educational video21
Glofitamab vs. real-world regimens in Chinese patients with third- or later-line relapsed/refractory diffuse large B-cell lymphoma: an external control study20
Progress toward cervical cancer elimination: global disparities and China’s contributions20
Ubiquitination in osteosarcoma: unveiling the impact on cell biology and therapeutic strategies19
Intricate roles of estrogen and estrogen receptors in digestive system cancers: a systematic review19
Biological insights in non-small cell lung cancer18
Enhancing cancer immunotherapy through polymer-based antibody conjugation technologies18
Conceptualizing the complexity of ferroptosis to treat triple-negative breast cancer: theory-to-practice17
Elucidating the synergistic roles of CD4+ T and dendritic cells in antitumor immunity17
Advances in antibody-drug conjugates for urothelial carcinoma treatment16
First-line immunotherapy for advanced non-small cell lung cancer: current progress and future prospects16
PD-1 and LAG-3 dual blockade: emerging mechanisms and potential therapeutic prospects in cancer16
Perspective on novel proteins encoded by circular RNAs in glioblastoma15
Neutrophils as key regulators of tumor immunity that restrict immune checkpoint blockade in liver cancer15
Current and future trends in whole genome sequencing in cancer15
Artificial intelligence-based comprehensive analysis of immune-stemness-tumor budding profile to predict survival of patients with pancreatic adenocarcinoma14
Alterations in DNA damage response and repair genes as potential biomarkers for immune checkpoint blockade in gastrointestinal cancer14
A quick and reliable image-based AI algorithm for evaluating cellular senescence of gastric organoids13
Liquid-liquid phase separation in DNA double-strand break repair13
Chromatin relaxation dynamics and histone PTMs in the early DNA damage response13
Deep proteome profiling promotes whole proteome characterization and drug discovery for esophageal squamous cell carcinoma13
Immunological and metabolic optimization of tumor neoantigen vaccines13
From dichotomy to diversity: deciphering the multifaceted roles of tumor-associated macrophages in cancer progression and therapy13
CAR T-cell therapy for relapsed/refractory CD5-positive diffuse large B-cell lymphoma yields more favorable outcomes than standard therapy13
BLM helicase inhibition synergizes with PARP inhibition to improve the radiosensitivity of olaparib resistant non-small cell lung cancer cells by inhibi12
Loss of NEIL3 activates radiotherapy resistance in the progression of prostate cancer12
PYK2 mediates the BRAF inhibitor (vermurafenib)-induced invadopodia formation and metastasis in melanomas11
The role of intestinal flora on tumorigenesis, progression, and the efficacy of PD-1/PD-L1 antibodies in colorectal cancer11
Anti-tumor pharmacology of natural products targeting mitosis11
Research progress in tumor angiogenesis and drug resistance in breast cancer11
Treatment strategies for patients with HER2-positive gastric cancer10
Next-generation antibody–drug conjugates revolutionize the precise classification and treatment of HER2-expressing breast cancer10
Current status of management of immune-related adverse events and practical needs for oncologist education10
A causal variant rs3769823 in 2q33.1 involved in apoptosis pathway leading to a decreased risk of non-small cell lung cancer10
Major roles of the circadian clock in cancer10
Single-arm trials for domestic oncology drug approvals in China10
Optimal immunotherapy duration in advanced NSCLC: defining the ideal treatment window10
Drug clinical trials on high-grade gliomas: challenges and hopes10
The evidence and concerns about screening ultrasound for breast cancer9
Cancer risk in relatives of BRCA1/2 pathogenic variant carriers in a large series of unselected patients with breast cancer9
Potential treatment approaches for malignant peritoneal mesothelioma: in vivo and in vitro experimental study of natural killer cell immunotherapy9
Recent progress in targeting the sialylated glycan-SIGLEC axis in cancer immunotherapy9
Early detection of gastric cancer in China: progress and opportunities9
MicroRNA-384 radiosensitizes human non-small cell lung cancer by impairing DNA damage response and repair signaling, which is inhibited by NF-κB9
Chidamide suppresses macrophage-mediated immune evasion and tumor progression in small cell lung cancer by targeting the STAT4/CCL2 signaling pathway9
Association between homologous recombination deficiency and outcomes with platinum and platinum-free chemotherapy in patients with triple-negative breast cancer9
Chinese Society of Clinical Oncology Breast Cancer (CSCO BC) guidelines in 2022: stratification and classification9
Metabolic regulation of immune responses to cancer9
The HDAC inhibitor GCJ-490A suppresses c-Met expression through IKKα and overcomes gefitinib resistance in non-small cell lung cancer8
Erratum to DYRK1A suppression restrains Mcl-1 expression and sensitizes NSCLC cells to Bcl-2 inhibitors8
Identifying occult high-risk features and stratified management strategies following curative resection for ampullary adenocarcinoma8
Modeling cervical cancer elimination: a pathway to inform policy decisions8
Understanding the mechanisms underlying obesity in remodeling the breast tumor immune microenvironment: from the perspective of inflammation8
Epigenetic regulators as the foundation for molecular classification of colorectal cancer8
Decoding the complexity of metastasis8
N6-methyladenosine (m6A) RNA modification in tumor immunity8
Treatment strategies for advanced neuroendocrine neoplasms: current status and future prospects8
Large-scale loss-of-function perturbations reveal a comprehensive epigenetic regulatory network in breast cancer8
Development of glioblastoma organoids and their applications in personalized therapy7
Senescent macrophages in cancer: roles in tumor progression and treatment opportunities7
Erianin inhibits the proliferation of lung cancer cells by suppressing mTOR activation and disrupting pyrimidine metabolism7
Neoantigen cancer vaccines: a new star on the horizon7
Bilirubin inhibits the anticancer activity of sorafenib by blocking MCL-1 degradation in hepatocellular carcinoma cells7
Targeting PP2A for cancer therapeutic modulation7
A therapeutic multi-epitope protein vaccine targeting HPV16 E6 E7 elicits potent tumor regression and cytotoxic immune responses7
Azoximer bromide and hydroxyapatite: promising immune adjuvants in cancer7
MIIP inhibits clear cell renal cell carcinoma proliferation and angiogenesis via negative modulation of the HIF-2α-CYR61 axis7
Mutations in Ras homolog family member A in patients with peripheral T-cell lymphoma and implications for personalized medicine7
Erratum to Treatment strategies for patients with HER2-positive gastric cancer7
The inducible secreting TLR5 agonist, CBLB502, enhances the anti-tumor activity of CAR133-NK92 cells in colorectal cancer7
0.91173195838928